1. Home
  2. PCVX vs MMS Comparison

PCVX vs MMS Comparison

Compare PCVX & MMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PCVX
  • MMS
  • Stock Information
  • Founded
  • PCVX 2013
  • MMS 1975
  • Country
  • PCVX United States
  • MMS United States
  • Employees
  • PCVX N/A
  • MMS N/A
  • Industry
  • PCVX Biotechnology: Pharmaceutical Preparations
  • MMS Business Services
  • Sector
  • PCVX Health Care
  • MMS Consumer Discretionary
  • Exchange
  • PCVX Nasdaq
  • MMS Nasdaq
  • Market Cap
  • PCVX 4.4B
  • MMS 4.0B
  • IPO Year
  • PCVX 2020
  • MMS 1997
  • Fundamental
  • Price
  • PCVX $36.24
  • MMS $73.61
  • Analyst Decision
  • PCVX Strong Buy
  • MMS Buy
  • Analyst Count
  • PCVX 10
  • MMS 1
  • Target Price
  • PCVX $136.50
  • MMS $90.00
  • AVG Volume (30 Days)
  • PCVX 1.5M
  • MMS 389.4K
  • Earning Date
  • PCVX 08-05-2025
  • MMS 08-07-2025
  • Dividend Yield
  • PCVX N/A
  • MMS 1.63%
  • EPS Growth
  • PCVX N/A
  • MMS 31.21
  • EPS
  • PCVX N/A
  • MMS 5.00
  • Revenue
  • PCVX N/A
  • MMS $5,395,260,000.00
  • Revenue This Year
  • PCVX N/A
  • MMS $2.13
  • Revenue Next Year
  • PCVX N/A
  • MMS $3.36
  • P/E Ratio
  • PCVX N/A
  • MMS $14.75
  • Revenue Growth
  • PCVX N/A
  • MMS 5.29
  • 52 Week Low
  • PCVX $27.66
  • MMS $63.77
  • 52 Week High
  • PCVX $121.06
  • MMS $93.97
  • Technical
  • Relative Strength Index (RSI)
  • PCVX 55.76
  • MMS 59.95
  • Support Level
  • PCVX $35.25
  • MMS $70.58
  • Resistance Level
  • PCVX $37.95
  • MMS $72.36
  • Average True Range (ATR)
  • PCVX 1.54
  • MMS 1.57
  • MACD
  • PCVX 0.14
  • MMS 0.21
  • Stochastic Oscillator
  • PCVX 72.24
  • MMS 86.30

About PCVX Vaxcyte Inc.

Vaxcyte Inc is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its product comprises of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-31, VAX-24, VAX-A1, VAX-PG, VAX-GI, and Others.

About MMS Maximus Inc.

Maximus Inc designs, develops, and delivers programs, enabling people to access vital government services. It translates health and human services public policy into operating models that achieve outcomes for governments at scale. The company covers a broad array of services, including the operation of large health insurance eligibility and enrollment programs; clinical services, including assessments, appeals, and independent medical reviews; and technology services. The company operates through the following segments; U.S. Federal Services, U.S. Services, and Outside the U.S. A majority of its revenue is derived from the U.S. Federal Services segment which engages with various U.S. federal government agencies to deliver clinical services, maintenance services, and technology solutions.

Share on Social Networks: